Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
Earnings Data
Report Date
Sep 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.05Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -5.71%
|Next Earnings Date:Sep 30, 2025
Earnings Call Sentiment|Neutral
The earnings call indicates positive business development with a focus on revenue growth, patent protection, and cost management. However, financial challenges such as a net loss and decreased cash reserves present concerns.Company Guidance
During the Biofrontera's first quarter 2025 call, the company reported total revenues of $8.6 million, marking a 9% increase compared to the previous year. The cost of revenues decreased by 22.1% to $3.1 million, attributed to a revised cost structure under the Ameluz license agreement. Operating expenses also dropped slightly to $13.1 million from $13.4 million in the prior year. Notably, the company reduced selling, general, and administrative expenses by 6.5%. Despite increased R&D expenses due to taking over clinical trial activities, the net loss was significantly reduced to $4.2 million from $10.4 million the previous year, translating to a decrease in loss per share from $2.88 to $0.47. Adjusted EBITDA improved, reflecting a rise in gross profit by $1.5 million. The company also achieved several strategic milestones, including a new patent for Ameluz, advancing clinical trials, and expanding product indications. Biofrontera ended the quarter with $1.8 million in cash and equivalents and $6.5 million in inventory.Revenue Growth
Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.
Patent Protection
Biofrontera received a patent for the new formulation of Ameluz, extending protection from generic competition until December 2043.
Clinical Trial Progress
Enrollment of the final patient in Phase III clinical trial for Ameluz for the treatment of actinic keratoses on the extremities, neck, and trunk.
Cost Management
Total operating expenses were reduced to $13.1 million from $13.4 million in the same quarter of the previous year.
Improved EBITDA
Adjusted EBITDA improved from $4.6 million to $4.4 million year-over-year.
BFRI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BFRI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $0.70 | $0.65 | -7.14% |
Mar 21, 2025 | $1.03 | $0.86 | -16.50% |
Nov 13, 2024 | $0.83 | $0.70 | -15.66% |
Aug 14, 2024 | $1.14 | $1.16 | +1.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biofrontera (BFRI) report earnings?
Biofrontera (BFRI) is schdueled to report earning on Sep 30, 2025, TBA Not Confirmed.
What is Biofrontera (BFRI) earnings time?
Biofrontera (BFRI) earnings time is at Sep 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BFRI EPS forecast?
BFRI EPS forecast for the fiscal quarter 2025 (Q2) is -0.42.